Psychiatry & Neurology Doctors in Hobart, IN Accepting Medicare

4 Psychiatry & Neurology doctors found. Showing 1 - 4

Dr. Satya N Ramiah, D.O. Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 1500 S Lake Park Ave, Hobart, IN 46342 Phone: 219-947-6960    Fax: 219-947-6961

Mark A Simaga, MD Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 1600 S Lake Park Ave, Suite 1102, Hobart, IN 46342 Phone: 219-947-6960    Fax: 219-947-6960

Dr. George F Abu-aita, M.D. Psychiatry & Neurology - Clinical Neurophysiology Medicare: Accepting Medicare Assignments Practice Location: 1600 S Lake Park Ave Ste 1102, Hobart, IN 46342 Phone: 219-736-6955    Fax: 219-736-6080

Todd J Janus, PHD, MD Psychiatry & Neurology - Neurology Medicare: Medicare Enrolled Practice Location: 1600 S Lake Park Ave Ste 1103, Hobart, IN 46342 Phone: 219-947-6960    Fax: 219-947-6961

News Archive

Scientists expand their fleet of genomic next-generation sequencing technology to study about cancer

Scientists from the Baylor College of Medicine Human Genome Sequencing Center (HGSC) are expanding their fleet of advanced genomic next-generation sequencing technology from Applied Biosystems, part of Life Technologies Corporation to accelerate their studies of the genetic underpinnings of cancer and other complex human diseases.

Antiretroviral therapy does not increase severity of psychiatric disorders

A study of more than 300 children and adolescents with human immunodeficiency virus (HIV) revealed no association between specific antiretroviral therapy and the severity of psychiatric disorders.

Talecris granted EU orphan drug designation for Plasmin (human) to treat acute peripheral arterial occlusion

Talecris Biotherapeutics, Inc. (TLCR) announced today that it has been granted orphan drug designation by the European Commission for the development of Plasmin (human) to treat acute peripheral arterial occlusion (aPAO). Talecris is currently investigating Plasmin in a phase II clinical trial designed to assess its ability to treat aPAO, a condition in which arterial blood flow to the extremities, usually the legs, is blocked by a clot.

Scientists make breakthrough in developing new treatment for advanced bladder cancer

Scientists from Queen Mary University of London have made a breakthrough in developing a new therapy for advanced bladder cancer - for which there have been no major treatment advances in the past 30 years.

Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Tablets 80 mg

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998.

Read more Medical News

› Verified 3 days ago